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Abstract
Aims/hypothesis Type 2 diabetes confers a greater relative increase in CVD risk in women compared with men. We examined sex
differences in intraorgan fat and hepatic VLDL1-triacylglycerol (VLDL1-TG) export before and after major dietary weight loss.
Methods Agroupwith type2diabetes (n = 64,30male/34 female) andagroupofhealthy individuals (n = 25,13male/12 female)were
studied. Intraorgan and visceral fat were quantified bymagnetic resonance andVLDL1-TG export by intralipid infusion techniques.
Results Triacylglycerol content of the liver and pancreas was elevated in people with diabetes with no sex differences (liver
16.4% [9.3–25.0%] in women vs 11.9% [7.0–23.1%] in men, p = 0.57, and pancreas 8.3 ± 0.5% vs 8.5 ± 0.4%, p = 0.83,
respectively). In the absence of diabetes, fat levels in both organs were lower in women than men (1.0% [0.9–1.7%] vs 4.5%
[1.9–8.0%], p = 0.005, and 4.7 ± 0.4% vs 7.6 ± 0.5%, p< 0.0001, respectively). Women with diabetes had higher hepatic
VLDL1-TG production rate and plasma VLDL1-TG than healthy women (559.3 ± 32.9 vs 403.2 ± 45.7 mg kg−1 day−1, p =
0.01, and 0.45 [0.26–0.77] vs 0.25 [0.13–0.33] mmol/l, p = 0.02), whereas there were no differences in men (548.8 ± 39.8 vs
506.7 ± 29.2 mg kg−1 day−1, p = 0.34, and 0.72 [0.53–1.15] vs 0.50 [0.32–0.68] mmol/l, p = 0.26). Weight loss decreased
intraorgan fat and VLDL1-TG production rates regardless of sex, and these changes were accompanied by similar rates of
diabetes remission (65.4% vs 71.0%) and CVD risk reduction (59.8% vs 41.5%) in women and men, respectively.
Conclusions/interpretation In type 2 diabetes, women have liver and pancreas fat levels as high as those of men, associated with
raised hepatic VLDL1-TG production rates. Dynamics of triacylglycerol turnover differ between sexes in type 2 diabetes and
followingweight loss. These changes may contribute to the disproportionately raised cardiovascular risk of womenwith diabetes.
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SAT Subcutaneous adipose tissue
VAT Visceral adipose tissue
VLDL1-TG VLDL1-triacylglycerol
Introduction
The development of type 2 diabetes causes a disproportion-
ately increased risk of CVD in women, approaching that of
men [1]. The higher subcutaneous fat (SAT) in women may
normally provide greater safe storage of excess body fat
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potentially underpinned by a difference in hepatic fat
metabolism.
Excess fat accumulation within the liver increases hepatic
VLDL1-triacylglycerol (VLDL1-TG) export and plasma
VLDL1-TG concentration. We have confirmed this aspect
of the twin cycle hypothesis during both remission and rede-
velopment of diabetes [2]. This hypothesis postulates that type
2 diabetes results from linked vicious cycles leading to excess
accumulation of triacylglycerol in the liver and pancreas.
Excess VLDL1-TG export will deliver triacylglycerols not
only to the pancreas, causing beta cell dysfunction, but also
to all sites of ectopic fat accumulation, causing deposition of
lipoprotein remnants in coronary and cerebral arteries,
increasing CVD risks.
There are few lipid-related studies of women with diabetes,
and many studies have overlooked the influence of sex, and
the differences underlying the increased CVD of women have
not been satisfactorily explained [1, 3]. The primary aim of
this study was to quantify the differences in intraorgan fat
deposition, hepatic lipoprotein metabolism and CVD risk
between women and men with type 2 diabetes and how these
variables change after dietary weight loss.
Methods
Participants and study design This study is part of DiRECT
(n = 64, 30male/34 female; age, 52.3 ± 1.0 years; BMI, 35.1
± 0.6 kg/m2 [2, 4]). The nondiabetic group (13 male/12
female; age, 55.8 ± 1.2 years; BMI, 29.7 ± 0.8 kg/m2) was
selected to match the diabetes group after weight loss.
Metabolic studieswere carried out at baseline and after dietary
weight loss (electronic supplementary material [ESM] Fig. 1).
Ethics approval DiRECT is cl inical ly regis tered
(ISRCTN03267836). Ethical approval was obtained from
the West of Scotland and Newcastle and North Tyneside
Ethics Committees, and written informed consent was obtain-
ed from all participants prior to the study.
Quantification of VLDL1-TG This was performed using a
non-isotopic method [5]. Density gradient ultracentrifuga-
tion technique was used to separate the VLDL1 fraction.
Magnetic resonance studies Magnetic resonance (MR) data
were acquired using a 3.0 Tesla scanner (Philips, the
Netherlands). The protocol includes 3-point Dixon acquisi-
tion, and MR-opsy/watershed methods for intrapancreatic
fat/abdominal fat measurement [6].
Remission of diabetes This was defined as HbA1c< 6.5%
(48.0 mmol/mol) and fasting blood glucose <7.0 mmol/l
off any glucose-lowering medication. Relapsers were
defined as individuals who lost remission based on the
same criteria.
Biochemical and CVD risk analyses Triacylglycerol, insulin,
glucose and other blood metabolites were measured by
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Table 1 Clinical and metabolic characteristics in men and women at baseline and after weight loss
Characteristic Baseline
(n=64, 34 M/30 F)
5 months
(n=57, 31 M/26 F)
12 months
(n=48, 27 M/21 F)
24 months
(n=45, 25 M/20 F)
ND
(n=25, 13 M/12 F)
Age (year)
Men 53.5±1.2 – 55.1±1.3 56.7±1.3 55.5±1.5
Women 52.3±1.7 – 53.5±2.0 53.9±2.0 56.0±2.0
Diabetes duration (year)
Men 3.2±0.3 – 4.2±0.3 5.2±0.3 –
Women 2.9±0.3 – 3.9±0.3 4.9±0.3 –
Weight (kg)
Men 108.1±3.2 90.6±3.0*** 93.4±3.3 95.8±3.3 95.6±3.0
Women 92.4±2.3‡‡‡ 79.5±2.2***‡‡ 81.8±2.9‡ 84.7±3.1‡ 76.9±3.6‡‡
BMI (kg/m2)
Men 34.7±0.8 29.1±0.8 30.3±0.9 31.1±0.8 30.6±0.8‡‡
Women 35.7±0.9 30.7±0.9 31.7±1.2 31.7±1.2 28.8±1.3‡‡‡
Fasting glucose (mmol/l)
Men 8.1 (7.3–9.6)††† 6.2 (5.3–6.8)*** 5.9 (5.5–7.1)*** 6.0 (5.4–6.7)*** 5.3 (4.9–5.4)
Women 7.8 (6.6–10.4)††† 6.6 (5.2–7.1)** 6.3 (5.5–7.5)* 6.7 (6.2–9.4) 5.1 (4.8–5.3)
HbA1c (mmol/mol)
Men 58.0 (54.5–63.0)††† 42.0 (38.0–47.0)*** 42.3 (38.2–54.3)*** 47.0 (41.0–53.0)** 35.0 (32.0–38.0)
Women 57.0 (48.8–66.0)††† 46.0 (43.0–52.3)** 45.4 (40.3–57.5)** 57.5 (45.0–73.0) 36.0 (34.3–37.3)
HbA1c (%)
Men 7.5 (7.1–7.9) 6.0 (5.6–6.5) 6.0 (5.6–7.1) 6.5 (5.9–7.0) 5.4 (5.1–5.6)
Women 7.4 (6.6–8.2) 6.4 (6.1–6.9) 6.3 (5.8–7.4) 7.4 (6.3–8.8) 5.4 (5.3–5.6)
Total cholesterol (mmol/l)
Men 3.9±0.2†† – 3.9±0.2 4.5±0.2* 5.1±0.3
Women 4.7±0.2‡‡ – 4.8±0.3‡‡ 5.4±0.3*‡ 5.3±0.2
HDL-cholesterol (mmol/l)
Men 0.96±0.04†† – 1.13±0.06* 1.18±0.05*** 1.29±0.09
Women 1.16±0.05‡‡†† – 1.29±0.09 1.40±0.12*** 1.57±0.11
Fasting insulin (pmol/l)
Men 99.5 (54.9–142.0)††† 24.5 (19.1–45.0)*** 28.5 (18.6–65.5)*** 37.0 (16.0–61.6)*** 32.8 (16.2–45.6)
Women 75.3 (55.0–113.0)††† 37.3 (29.4–52.3)*** 43.2 (23.0–59.4)*** 47.1 (32.7–63.0)** 11.3 (6.1–17.7)‡
Fasting glucagon (pg/ml)
Men 25.0 (20.5–39.0)† 14.0 (11.0–18.5)*** 16.0 (13.0–27.0)** 23.0 (13.0–30.3)* 21.0 (14.0–23.0)
Women 21.0 (17.0–25.5)‡††† 17.0 (11.0–22.5) 16.0 (13.0–25.0) 17.0 (14.0–28.5) 7.5 (5.0–13.3)‡‡
Liver fat (%)
Men 11.9 (7.0–23.1)††† 1.3 (1.2–1.9)*** 1.5 (1.3–2.9)*** 4.1 (2.4–6.4)*** 4.5 (1.9–8.0)
Women 16.4 (9.3–25.0)††† 1.8 (1.2–6.1)*** 3.5 (1.2–9.4)*** 8.3 (7.1–13.4)‡‡** 1.0 (0.9–1.7)‡‡
Pancreas fat (%)
Men 8.5±0.4 7.6±0.4*** 7.2±0.4*** 7.5±0.4*** 7.6±0.5
Women 8.3±0.5††† 7.5±0.5*** 7.6±0.4** 7.7±0.6* 4.7±0.4‡‡‡
VLDL1-TG PR (mg kg−1 day−1)
Men 548.8±39.8 417.7±28.4** 494.2±42.3* 539.3±37.4 506.7±29.2
Women 559.3±32.9† 474.6±37.0* 548.3±38.7 560.2±38.6 403.2±45.7
Plasma VLDL1-TG (mmol/l)
Men 0.72 (0.53–1.15) 0.23 (0.15–0.56)*** 0.47 (0.25–0.79)* 0.73 (0.37–0.88) 0.50 (0.32–0.68)













standard methods [2]. The QRISK3 (https://qrisk.org/three)
was used to assess CVD risk.
Statistical analysis The study was powered as described previ-
ously [2]. At each time point, the primary outcome is the
differences between women and men. Data are presented as
mean ± SEM or median and IQR. Student’s t, Mann–
Whitney U or Wilcoxon signed rank tests were employed as
appropriate. ANOVA assessed the difference between women
and men over time after adjusting for body weight. Minitab
and SPSS were used for all statistical analyses. A p value <
0.05 was considered statistically significant.
Results
Baseline characteristicsData are presented in Table 1. Women
and men were well matched for age, BMI and diabetes dura-
tion. Fasting insulin was lower in nondiabetic women than
men, and this was not seen in individuals with diabetes.
Fasting glucagon was lower in nondiabetic women than men
and was similar in diabetes.
In the nondiabetic group, liver fat in women was 22% that
of men (4.5% [1.9–8.0%] vs 1.0% [0.9–1.7%], p = 0.005),
and this difference was lost in individuals with diabetes
(16.4% [9.3–25.0%] vs 11.9% [7.0–23.1%], p = 0.57).
Similarly, pancreas fat in nondiabetic women was 62% that
of men (4.7 ± 0.4% vs 7.6 ± 0.5%, p< 0.001) but was almost
identical in individuals with diabetes (8.3 ± 0.5% vs 8.5 ±
0.4%, p = 0.83).
Compared with the nondiabetic group, women with
diabetes had a 39% higher mean VLDL1-TG production
rate (559.3 ± 32.9 vs 403.2 ± 45.7 mg kg−1 day−1, p =
0.01), whereas men with those with diabetes had an 8%
higher VLDL1-TG production rate (548.8 ± 39.8 vs
506.7 ± 29.2 mg kg−1 day−1, p = 0.40). In the nondia-
betic group, VLDL1-TG production rates were numerical-
ly but not significantly lower in women than men but
Table 1 (continued)
Characteristic Baseline
(n = 64, 34 M/30 F)
5 months
(n = 57, 31 M/26 F)
12 months
(n = 48, 27 M/21 F)
24 months
(n = 45, 25 M/20 F)
ND












Men 1.9 (1.3–2.3) 1.1 (0.7–1.5)*** 1.1 (0.8–1.6)*** 1.2 (0.8–1.7)** 1.5 (1.0–1.60)
Women 1.5 (1.1–2.1)†† 1.1 (0.9–1.4)* 1.3 (0.9–1.7) 1.3 (0.9–1.8) 0.9 (0.7–1.2)
Fasting NEFA (mmol/l)
Men 0.53±0.03 0.53±0.03 0.53±0.03 0.55±0.04 0.57±0.07
Women 0.67±0.04‡‡ 0.60±0.04 0.59±0.04* 0.72±0.03‡‡ 0.58±0.03
Ketones (mmol/l)
Men 0.10 (0.10–0.20)† 0.20 (0.10–0.30)* 0.20 (0.15–0.30)* 0.20 (0.18–0.30)* 0.20 (0.20–0.30)
Women 0.20 (0.10–0.28) 0.20 (0.13–0.20) 0.20 (0.20–0.23) 0.20 (0.18–0.23) 0.30 (0.20–0.30)
SAT (cm2)
Men 239.3±15.0 162.0±14.0*** 209.6±20.3*** 231.8±20.2* 250.3±25.2
Women 397.4±21.8‡‡‡†† 318.4±21.9*** 341.6±27.4** 350.5±25.2** 279.5±29.2
VAT (cm2)
Men 320.9±12.4 158.1±12.7*** 196.6±14.0*** 244.8±15.6*** 287.3±19.7
Women 226.6±12.3‡‡‡†††† 158.2±12.2*** 156.6±17.3*** 173.1±14.9** 92.8±16.0‡‡‡
QRISK3 (%)
Men 14.7 (10.0–18.5)†† 8.6 (5.9–11.9)*** 8.2 (5.8–10.0)*** 8.6 (6.8–11.7)* 7.3 (6.5–10.5)
Women 10.2 (7.0–14.8)‡††† 4.1 (2.9–6.7)‡‡*** 6.2 (3.8–8.7)*** 7.3 (5.3–11.5)* 4.4 (2.9–6.7)‡
Heart age (year)
Men 67.8±1.2†† 60.4±1.3*** 59.9±1.3*** 62.3±1.6** 59.5±2.1
Women 69.1±1.2††† 59.2±1.7*** 62.0±1.8** 63.6±1.8* 57.9±2.0
Paired data with 5 months were presented at baseline (baseline data for those who competed the study was similar to the whole group). Data were
presented mean ± SEM or median (IQR) based on distribution
*p < 0.05 vs baseline, **p < 0.01 vs baseline, ***p < 0.001 vs baseline; †p < 0.05 vs ND, ††p < 0.01 vs ND, †††p < 0.001 vs ND; ‡ p < 0.05 men vs
women, ‡‡ p < 0.01 men vs women, ‡‡‡p < 0.001 men vs women
F, female; M, male; ND, nondiabetic; TG, triacylglycerol; VLDL1-TG PR, VLDL1-TG production rate
Diabetologia
almost identical between sexes in individuals with diabe-
tes. Fasting plasma VLDL1-TG levels in nondiabetic
women were 50% lower than men (0.25 [0.13–0.33] vs
0.50 [0.32–0.68] mmol/l, respectively, p = 0.008), where-
as in indivduals with \diabetes, levels in women were
63% of those of men (0.45 [0.26–0.77] vs 0.72 [0.53–
1.15] mmol/l, p = 0.014. This was reflected in the
VLDL1-TG pool size. The fasting plasma NEFA level
was identical between women and men in the nondiabetic
group but higher in women with diabetes.
Fig. 1 Changes in lipid variables
after weight loss in women and
men. Changes from the baseline
(Δ values) at 5, 12 and 24 months
are presented. Statistics within
each group reflected the
difference between actual values,
and statistics between groups
were calculated based on the
difference in the absolute change
at each time point between men
and women. Changes in (a) body
weight, (b) fasting plasma insulin,
(c) liver fat, (d) pancreas fat, (e)
VLDL1-TG production rate, (f)
plasma VLDL1-TG, (g) total
plasma TG and (h) NEFA are
shown for men (dashed line) and
women (solid line). Data are
presented as mean ± SEM.
**p < 0.01, ***p < 0.001 vs
baseline (men); †p < 0.05, ††p <
0.01, †††p < 0.001 vs baseline
(women); ‡p < 0.05, ‡‡‡p <




There was a major difference in CVD risk between diabetes
and nondiabetic groups (Table 1). In the nondiabetic group,
women had visceral adipose tissue (VAT) 32% of male
values, but it was 71% ofmale values in women with diabetes.
The CVD risk was almost twofold higher in men than women
in the nondiabetic group (7.3% [6.5–10.5%] vs 4.4% [2.9–
6.7%], p = 0.021) and less so in diabetes (14.7% [10.0–
18.5%] vs 10.2% [7.0–14.8%], p = 0.049). Despite similar
actual age, the estimated heart age was higher for both women
and men with diabetes (69.1 ± 1.2 vs 57.9 ± 2.0 years, p<
0.0001, and 67.8 ± 1.2 vs 59.5 ± 2.1 years, p = 0.003,
respectively).
Changes in lipid variables after weight loss Change from
baseline in BMI immediately after weight loss was similar in
women and men (−5.0 ± 0.5 vs −5.6 ± 0.4 kg/m2, p = 0.31)
although absolute weight loss was lower in women than men
(−12.9 ± 1.2 vs −17.5 ± 1.4 kg, p = 0.02, Table 1).
Remission of diabetes immediately after weight loss was
observed in 65.4% and 71.0% in women and men.
Liver fat decreased similarly in women and men (to 1.8%
[1.2–6.1], p < 0.0001, and 1.3% [1.2–1.9], p < 0.0001,
respectively) becoming almost identical to the nondiabetic
group.
VLDL1-TG production rate decreased similarly in women
and men (to 474.6 ± 37.0, p = 0.033, and 417.7 ±
28.4 mg kg−1 day−1, respectively, p = 0.001). However, plas-
ma VLDL1-TG did not change significantly in women (0.45
[0.26–0.77] to 0.44 [0.23–0.63] mmol/l, p = 0.92), although it
did fall in men (0.72 [0.53–1.15] to 0.23 [0.15–0.56] mmol/l,
p = 0.0001).
Total triacylglycerol decreased less in women compared
with men, and there were no significant changes in fasting
NEFA in either group. Pancreas fat and fasting insulin
decreased equally in both sexes, but fasting glucagon and
ketones levels changed significantly only in men (Table 1).
The decrease in VAT was smaller in women, although the
change in SAT was similar to men. CVD risk decreased mark-
edly after weight loss in both sexes (59.8% vs 41.5%) although
remained higher in men (Table 1). The estimated heart age
decreased, becoming similar to the nondiabetic group
(Table 1). CVD risk decreased to a greater extent in those who
achieved remission but returned to baseline level in relapsers
who gained weight and lost remission (data not shown).
Changes in lipid variables during the 2-year follow-up are
shown in Fig. 1.
Discussion
These data demonstrate clear sex differences in the dynamics
of hepatic fat handling in type 2 diabetes. Women normally
have lower liver and intrapancreatic fat than men, but these
sex differences are lost in diabetes.Women with diabetes have
a significantly increased VLDL1-TG production rate and
fasting plasma VLDL1-TG concentration compared with
nondiabetic women, with smaller differences in men.
However, women with diabetes have lower plasma VLDL1-
TG than men despite having the same level of liver fat and
hepatic VLDL1-TG production rate. Weight loss brought
about similar changes in intraorgan fat and VLDL1-TG
production rate but not fasting plasma VLDL1-TG
levels in both sexes. Estimated CVD risk was high in
diabetes, with substantial improvement in both sexes
after weight loss [7].
Plasma triacylglycerols were lower in women than men, and
the underlying mechanism to explain this difference is not
known. In lean nondiabetic individuals, the VLDL1-TG
production rate is higher in women than in men, but the reverse
is true in people with obesity [8]. In contrast, VLDL1-TG clear-
ance was higher in lean women than men despite their lower
rate of VLDL1-TG secretion [9]. We did not find any signifi-
cant difference in VLDL1-TG production rate between men
and women within each group. However, our nondiabetic
group represents people who are neither lean nor morbidly
obese. Collectively, our data suggest that the VLDL1-TG
production rate increases to a greater extent in women who
develop diabetes, consistent with a greater filling of intraorgan
fat, possibly due to reaching individual limits for SAT storage
capacity or change in the biology of adipocyte function.
Most overweight/obese people do not develop type 2
diabetes. This ‘metabolically healthy’ phenotype is genetical-
ly determined via alleles associated with higher SAT and
lower ectopic fat deposition [10]. Large SAT storage with
high expression of lipoprotein lipase (LPL) may increase the
uptake of the plasma VLDL1-TG. Stable-isotope studies have
shown the larger the SAT in women, the higher the uptake of
meal-derived fatty acids with the opposite for VAT [11]. The
contribution of de novo lipogenesis to VLDL1-TG synthesis
in men increases postprandially, suggesting preferential stor-
age of diet-derived fatty acids in the liver [12]. In women,
there is greater diversion of fatty acids towards ketones rather
than VLDL1-TG [13]. Taken together, women appear to have
more efficient mechanisms to clear excess fat, probably via
active uptake and deposition of excess fat within SAT. In our
study, women with diabetes had higher NEFA at baseline than
men, and differences in regional and plasma LPL activity may
underlie more rapid catabolism of plasma VLDL1-TG in
women.
Women normally have lower CVD risk, but this increases
to a greater extent in type 2 diabetes [1]. In this study, weight
loss improved the QRISK3 score substantially, becoming
similar to the nondiabetic level in both sexes. Oxidised LDL
remnants promote atherosclerosis, and women may be more
susceptible to cellular damage at lower levels of circulating
lipids. Non-lipid factors could also contribute to women’s
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increased risk of CVD in diabetes [3]. The underlying mech-
anisms explaining this sex difference are unclear and unlikely
to be affected by menopausal status (ESM Table 1). The
observed differences in hepatic fat handling appear relevant.
Weight loss was associated with a significant decrease of
VLDL1-TG production rate in both sexes but a lesser change
in plasma VLDL1-TG and VLDL1-TG pool size in women,
possibly a consequence of more rapid conversion of VLDL1
to VLDL2 in women [14].
There are potential limitations of this study: (1) the partic-
ipants remained substantially overweight despite major
weight loss and were not expected to achieve normal metab-
olism; and (2) the women had a lower weight at baseline,
despite similar BMI. However, the sex difference in the
VLDL1-TG pool remained significant after adjusting for lean
body mass estimated from Boer’s formula [15] or for body
weight using ANOVA; (3) we did not measure LPL activity or
lipoprotein clearance.
Overall, the data presented here demonstrate major metabol-
ic differences in lipid metabolism between sexes, which under-
lie differences in cardiovascular outcomes in type 2 diabetes.
Supplementary Information The online version contains peer-reviewed
but unedited supplementary material available at https://doi.org/10.1007/
s00125-021-05583-4.
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